Oral Mucositis Pipeline Report, H2 2017 - Therapeutic Review of 11 Companies & Drug Profiles - Research and Markets

DUBLIN--()--The "Oral Mucositis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Oral Mucositis - Pipeline Review, H2 2017 provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Oral Mucositis - Overview
  3. Oral Mucositis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Oral Mucositis - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Oral Mucositis - Companies Involved in Therapeutics Development
  • Clevexel Pharma SAS
  • Colby Pharmaceutical Company
  • Galera Therapeutics Inc
  • Humanetics Corp
  • Innovation Pharmaceuticals Inc
  • Onxeo SA
  • Oragenics Inc
  • Otsuka Holdings Co Ltd
  • Soligenix Inc
  • Spectrum Pharmaceuticals Inc
  • Spherium Biomed SL

For more information about this report visit https://www.researchandmarkets.com/research/zrrn88/oral_mucositis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs